Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice.
about
Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Oral histone deacetylase inhib ...... toimmune diabetes in NOD mice.
@en
Oral histone deacetylase inhib ...... toimmune diabetes in NOD mice.
@nl
type
label
Oral histone deacetylase inhib ...... toimmune diabetes in NOD mice.
@en
Oral histone deacetylase inhib ...... toimmune diabetes in NOD mice.
@nl
prefLabel
Oral histone deacetylase inhib ...... toimmune diabetes in NOD mice.
@en
Oral histone deacetylase inhib ...... toimmune diabetes in NOD mice.
@nl
P2093
P2860
P1433
P1476
Oral histone deacetylase inhib ...... toimmune diabetes in NOD mice.
@en
P2093
Alix Besançon
Fabrice Valette
Lucienne Chatenoud
Mattias S Dahllöf
Tania Goncalves
Thomas Mandrup-Poulsen
P2860
P2888
P304
P356
10.1007/S00125-017-4459-0
P50
P577
2017-10-13T00:00:00Z